BUSINESS

• DSP Subsidiary Sunovion Launches Antiepileptic Drug Aptiom in US
  April 9, 2014

• Livalo Lawsuit: Does Use of “PITAVA” by Generic Makers Infringe Kowa Trademark?
  April 9, 2014

• Ethical Drug Sales Up 3.0% in February Due to Flu Epidemic: Crecon Report
  April 9, 2014

• Bayer Yakuhin Sales Up 16.5% Driven by New Product Growth
  April 9, 2014

• Oncolys, BMS End Collaboration for Anti-HIV Drug Development
  April 9, 2014

• Santen Licenses Tafluprost Marketing Rights in US to Oak Pharmaceuticals
  April 9, 2014

• Sun Deal Not Meant to Sever Ties with Ranbaxy: Daiichi Sankyo Pres.
  April 8, 2014

• Daiichi Sankyo’s Governance over Ranbaxy Shaky to the End
  April 8, 2014

• Novartis Gives Update on SIGN Probe, Personnel Change to JPMA
  April 8, 2014

• Why Did Sanofi Decide to Begin Independent Marketing? Future Relationship with Nichi-Iko Remains in Doubt
  April 8, 2014

• Japan Generic Market Put at 780 Billion Yen in 2016, Biosimilars 26.4 Billion Yen: Fuji Keizai
  April 8, 2014

• India’s Sun Pharma to Acquire Ranbaxy via Equity Swap Deal, Taking Ranbaxy Off Daiichi Sankyo Scorecard
  April 7, 2014

• GSK’s Japan Unit Mulls Recalling Paxil after FDA Warning
  April 7, 2014

• Astellas Seeks European Approval of XTANDI for Chemotherapy-Naïve Prostate Cancer Patients
  April 7, 2014

• Latuda Approved for Bipolar Depression in Canada: DSP
  April 7, 2014

• Gilead’s Novel Hepatitis C Drug Beats Primary Endpoint in PIII, Filing Slated for Mid-Year
  April 7, 2014

• Novartis Replaces Japan Unit Head amid SIGN Trial Probe
  April 4, 2014

• Sanofi Japan Sales Down 3.9% as Generics Take Toll
  April 4, 2014

• Daiichi Sankyo Initiates Multinational ENSURE-AF Study of Edoxaban in the US, Europe
  April 4, 2014

• Sawai Stands Out with Operating Profit Rate of 25% in 3rd Quarter, Moving into Top Level of the Industry
  April 4, 2014

ページ

• « 先頭
• ‹ Prev
• …
• 570
• 571
• 572
• 573
• 574
• 575
• 576
• 577
• 578
• …
• Next ›
• 最終 »